CSL Behring Patent-Cliff Exposure & CMS Drug Spending Portfolio
CSL Behring (US): 15 reconciled FDA prescription therapies, $1.34B 2024 CMS Part D & Medicaid spend, and 89 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 15 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | Multi-asset schedule |
| 2024 CMS Total Public Spend | $1.34B |
| 2024 Medicare Part D Spend | $840.5M |
| 2024 Medicaid Spend | $497.7M |
| California HCAI SB 17 Filings | 89 WAC filings (max 25.2% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for CSL Behring across sibling Meru public-data platforms.